1. What are the recommendations for patients with RMD regarding the use of combined estrogen-progestin contraceptives?
2. What is the preferred approach for patients at risk for osteoporosis in terms of contraceptive options?
3. How should stress-dose glucocorticoids be administered during vaginal delivery according to the guideline?
4. What is the recommended approach for continuing tumor necrosis factor inhibitor therapy during pregnancy?
5. How do biologic therapies vary in terms of placental transfer and fetal exposure during pregnancy?
6. What is the panel's recommendation regarding the use of non-TNF inhibitor IgG-based molecules during the periconception period and pregnancy?
7. How should treatment with rituximab be managed in women trying to conceive and during pregnancy?
8. What is the guideline's stance on the use of small-molecule agents like tofacitinib, baricitinib, and apremilast during pregnancy?
9. What are the recommendations for breastfeeding while on RMD medications such as HCQ, colchicine, and TNF inhibitors?
10. How should breastfeeding be managed for women taking prednisone at different dose levels?